IDXXIdexx Laboratories
Valuation
What IDXX's price assumes
Idexx Laboratories trades at 45.5× earnings against 36.3× for the median Diagnostics & Research name.
Trailing P/E · Diagnostics & Research median 36.3 · 1.26× the Diagnostics & Research median
- Price / sales
- 11.4
Price / sales · today's price, trailing year to Sep 30, 2026
- Free cash flow yield
- 2.5%
Free cash flow yield · Diagnostics & Research median 3.1%
- Growth the price implies
- +15%
Growth the price implies · The price pays for +15% free cash flow growth a year for a decade; the business has delivered +24% a year over the last three.
Details›
- Price / booktoday's price, trailing year to Sep 30, 2026
- 28.5
- EV / EBITtoday's price, trailing year to Sep 30, 2026
- 35.7
- EV / salestoday's price, trailing year to Sep 30, 2026
- 11.6
- Healthcare median P/E497 names
- 27.1
- Diagnostics & Research median P/E33 names
- 36.3
- Free cash flow, trailing twelve months
- $1.30B
- Market capitalisation78.8 million shares, counted Oct 28, 2026
- $53.3B
- 3-year revenue growth
- +9.1%
- 3-year free cash flow growth
- +24%
Multiples from SEC filings and end-of-day closes; implied growth from a reverse discounted cash flow. Group medians across the names Ryufin tracks.
Against its own past
Its multiples now against their own history, and how much of the price move came from earnings rather than the multiple.
Diagnostics & Research
The closest names by size in the same industry